The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation
Open accessAbstract
Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic signaling proteins that participates in normal cellular responses to cytokines and growth factors. Frequently, however, constitutive activation of certain STAT family members, particularly Stat3, has accompanied a wide variety of human malignancies. To identify small molecule inhibitors of Stat3, we investigated the ability of the Stat3 SH2 domain-binding peptide, PY*LKTK (where Y* represents phosphotyrosine), to disrupt Stat3 activity in vitro. The presence of PY*LKTK, but not PYLKTK or PFLKTK, in nuclear extracts results in significant reduction in the levels of DNA binding activities of Stat3, to a lesser extent of Stat1, and with no effect on that of Stat5. Analyses of alanine scanning mutagenesis and deletion derivatives of PY*LKTK reveal that the Leu residue at the Y+1 position and a substituent at the Y-1 position (but not necessarily Pro) are essential for the disruption of active Stat3, thereby mapping the minimum active sequence to the tripeptide, XY*L. Studies involving bead-coupled PY*LKTK peptide demonstrate that this phosphopeptide directly complexes with Stat3 monomers in vitro, suggesting that PY*LKTK disrupts Stat3:Stat3 dimers. As evidence for the functional importance of peptide-directed inhibition of Stat3, PY*LKTK-mts (mts, membrane translocating sequence) selectively inhibits constitutive and ligand-induced Stat3 activation in vivo. Furthermore, PY*LKTK-mts suppresses transformation by the Src oncoprotein, which has been shown previously to require constitutive Stat3 activation. Altogether, we have identified a minimal peptide that inhibits Stat3 signaling and provides the conceptual basis for use of this peptide as a lead for novel peptidomimetic drug design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway
Schindler, C., & Darnell, J. E. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003201 · Cited by 1,808
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Self-citationCatlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationLiver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice
Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., & Taub, R. (1996) · Science · doi:10.1126/science.274.5291.1379 · Cited by 1,538
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality
Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T., & Akira, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3801 · Cited by 1,323
Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease
Durbin, J. E., Hackenmiller, R., Simon, M. C., & Levy, D. E. (1996) · Cell · doi:10.1016/s0092-8674(00)81289-1 · Cited by 1,242
Cited by
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Self-citationTargeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Self-citationCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Self-citationStattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Targeting STAT3 in Cancer Immunotherapy
Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,050
Interleukin-6 Is an Essential Regulator of Satellite Cell-Mediated Skeletal Muscle Hypertrophy
Serrano, A. L., Baeza-Raja, B., Perdiguero, E., Jardí, M., & Muñoz-Cánoves, P. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.011 · Cited by 873
Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 770
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., Yip, M. L. R., Jove, R., McLaughlin, M. M., Lawrence, N. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609757104 · Cited by 736
Self-citationJAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Salas, A., Hernandez-Rocha, C., Duijvestein, M., Faubion, W., McGovern, D., Vermeire, S., Vetrano, S., & Vande Casteele, N. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0273-0 · Cited by 635
Constitutive activation of STAT 3 in breast cancer cells: A review
Banerjee, K., & Resat, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.29923 · Cited by 611
STAT proteins: From normal control of cellular events to tumorigenesis
Calò, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., & Russo, A. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10364 · Cited by 610
Radaeva, S., Sun, R., Pan, H.-N., Hong, F., & Gao, B. (2004) · Hepatology · doi:10.1002/hep.20184 · Cited by 597
Xu, Q., Briggs, J., Park, S., Niu, G., Kortylewski, M., Zhang, S., Gritsko, T., Turkson, J., Kay, H., Semenza, G. L., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208719 · Cited by 576
Self-citationGritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
Self-citationRecent advances in the use of cell-penetrating peptides for medical and biological applications☆
Fonseca, S. B., Pereira, M. P., & Kelley, S. O. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.001 · Cited by 553
Bharti, A. C., Donato, N., & Aggarwal, B. B. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3863 · Cited by 508
Song, H., Wang, R., Wang, S., & Lin, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409894102 · Cited by 504
STAT3 as a target for inducing apoptosis in solid and hematological tumors
Al Zaid Siddiquee, K., & Turkson, J. (2008) · Cell Research · doi:10.1038/cr.2008.18 · Cited by 487
Self-citationRoles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
Self-citationHaura, E. B., Turkson, J., & Jove, R. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0195 · Cited by 430
Self-citationTherapeutic modulators of STAT signalling for human diseases
Miklossy, G., Hilliard, T. S., & Turkson, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4088 · Cited by 413
Self-citationTargeting STAT3 in cancer: how successful are we?
Yue, P., & Turkson, J. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802565791 · Cited by 413
Self-citationNovel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation
Yang, J., Chatterjee-Kishore, M., Staugaitis, S. M., Nguyen, H., Schlessinger, K., Levy, D. E., & Stark, G. R. (2005) · Cancer Research · doi:10.1158/0008-5472.939.65.3 · Cited by 405
AGGARWAL, B. B., SETHI, G., AHN, K. S., SANDUR, S. K., PANDEY, M. K., KUNNUMAKKARA, A. B., SUNG, B., & ICHIKAWA, H. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1378.063 · Cited by 398
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J., Cress, W. D., Pardoll, D., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 392
Self-citationSTAT3 as a central mediator of neoplastic cellular transformation
Frank, D. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.10.017 · Cited by 364
Strategies and Approaches of Targeting STAT3 for Cancer Treatment
Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00945 · Cited by 347
Zhang, X., Yue, P., Page, B. D. G., Li, T., Zhao, W., Namanja, A. T., Paladino, D., Zhao, J., Chen, Y., Gunning, P. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121606109 · Cited by 344
Self-citationTargeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
Leong, P. L., Andrews, G. A., Johnson, D. E., Dyer, K. F., Xi, S., Mai, J. C., Robbins, P. D., Gadiparthi, S., Burke, N. A., Watkins, S. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0534764100 · Cited by 340
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway
de la Iglesia, N., Konopka, G., Puram, S. V., Chan, J. A., Bachoo, R. M., You, M. J., Levy, D. E., DePinho, R. A., & Bonni, A. (2008) · Genes & Development · doi:10.1101/gad.1606508 · Cited by 336
Signal transducer and activator of transcription proteins in leukemias
Benekli, M., Baer, M. R., Baumann, H., & Wetzler, M. (2003) · Blood · doi:10.1182/blood-2002-04-1204 · Cited by 325
Nakanishi, M., Niidome, T., Matsuda, S., Akaike, A., Kihara, T., & Sugimoto, H. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05309.x · Cited by 325
The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy
Tolomeo, M., & Cascio, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020603 · Cited by 318
STAT proteins as novel targets for cancer drug discovery
Turkson, J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.409 · Cited by 295
Self-citationSTAT‐mediated EGFR signaling in cancer
Quesnelle, K. M., Boehm, A. L., & Grandis, J. R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21475 · Cited by 295
Highlighted STAT3 as a potential drug target for cancer therapy
Lee, H., Jeong, A. J., & Ye, S.-K. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.7.152 · Cited by 295
Caldwell, R. B., Bartoli, M., Behzadian, M. A., El‐Remessy, A. E. B., Al‐Shabrawey, M., Platt, D. H., & Caldwell, R. W. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.415 · Cited by 293
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Xiong, A., Yang, Z., Shen, Y., Zhou, J., & Shen, Q. (2014) · Cancers · doi:10.3390/cancers6020926 · Cited by 283
Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A. S., Carter, B., Turkson, J., & Jove, R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0268 · Cited by 283
Self-citationTargeting STAT3 affects melanoma on multiple fronts
Kortylewski, M., Jove, R., & Yu, H. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1580-1 · Cited by 280
Self-citationTargeting Stat3 in cancer therapy
Jing, N., & Tweardy, D. J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00002 · Cited by 278
The Biology of Epidermal Growth Factor Receptor in Lung Cancer
Scagliotti, G. V., Selvaggi, G., Novello, S., & Hirsch, F. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040007 · Cited by 270
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
Hu, Y., Dong, Z., & Liu, K. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02949-5 · Cited by 268
Hall, C. J., Boyle, R. H., Astin, J. W., Flores, M. V., Oehlers, S. H., Sanderson, L. E., Ellett, F., Lieschke, G. J., Crosier, K. E., & Crosier, P. S. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.018 · Cited by 266
“Cell Metabolism 18, 265–27 a requirement for JAK/STAT signaling during infection-responsive irg1 expression, we utilized the cell-permeable JAK inhibitor AG490 and the STAT3specific inhibitor (STAT3 inhibitor peptide/PpYLKTK-mts) (Funakoshi-Tago et al., 2011; Turkson et al., 2001).”
Mutational switch of an IL-6 response to an interferon-γ-like response
Costa-Pereira, A. P., Tininini, S., Strobl, B., Alonzi, T., Schlaak, J. F., Is'harc, H., Gesualdo, I., Newman, S. J., Kerr, I. M., & Poli, V. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122236099 · Cited by 264
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity
Sun, J., Blaskovich, M. A., Jove, R., Livingston, S. K., Coppola, D., & Sebti, S. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208470 · Cited by 263
Self-citationCell-penetrating peptides transport therapeutics into cells
Ramsey, J. D., & Flynn, N. H. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.07.003 · Cited by 256
Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M., Haura, E., Sebti, S., Hamilton, A. D., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.261.3.3 · Cited by 255
Self-citationLo, H.-W., Cao, X., Zhu, H., & Ali-Osman, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4923 · Cited by 253
Activation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation
Yoshida, T., Hanada, T., Tokuhisa, T., Kosai, K.-I., Sata, M., Kohara, M., & Yoshimura, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012127 · Cited by 236
Critical role of STAT3 in leptin's metabolic actions
Buettner, C., Pocai, A., Muse, E. D., Etgen, A. M., Myers, M. G., & Rossetti, L. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.014 · Cited by 228
Identification of the Critical Features of a Small Peptide Inhibitor of JNK Activity
Barr, R. K., Kendrick, T. S., & Bogoyevitch, M. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107565200 · Cited by 211
The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations
Geiger, J. L., Grandis, J. R., & Bauman, J. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.022 · Cited by 193
Turkson, J., Zhang, S., Palmer, J., Kay, H., Stanko, J., Mora, L. B., Sebti, S., Yu, H., & Jove, R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1533.3.12 · Cited by 188
Self-citationZhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., & Turkson, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.001 · Cited by 179
Self-citationMitochondrial Stat3, the need for design thinking
Yang, R., & Rincon, M. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15153 · Cited by 147
“Tagging a membrane translocation sequence to the PY*LKTK peptide suppresses cancer transformation and cancer growth [119, 120].”
BackgroundSrivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S. S., Jugold, M., Besemfelder, E., Thomas, M., Pasparakis, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.005 · Cited by 140
Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3925 · Cited by 131
Identification of a High-Affinity Phosphopeptide Inhibitor of Stat3
Ren, Z., Cabell, L. A., Schaefer, T. S., & McMurray, J. S. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)01050-8 · Cited by 128
Ahmad, R., Raina, D., Meyer, C., & Kufe, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3036 · Cited by 120
Izumi, T., Imai, J., Yamamoto, J., Kawana, Y., Endo, A., Sugawara, H., Kohata, M., Asai, Y., Takahashi, K., Kodama, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07747-0 · Cited by 109
Weerasinghe, P., Garcia, G., Zhu, Q., Yuan, P., Feng, L., Mao, L., & Jing, N. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.1.129 · Cited by 95
IL-6 signaling via the STAT3/SOCS3 pathway: functional analysis of the conserved STAT3 N-domain
Zhang, L., Badgwell, D. B., Bevers, J. J., Schlessinger, K., Murray, P. J., Levy, D. E., & Watowich, S. S. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-9137-3 · Cited by 89
Fatih, N., Camberlein, E., Island, M. L., Corlu, A., Abgueguen, E., Détivaud, L., Leroyer, P., Brissot, P., & Loréal, O. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0588-3 · Cited by 59
Shao, H., Xu, X., Mastrangelo, M.-A. A., Jing, N., Cook, R. G., Legge, G. B., & Tweardy, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314037200 · Cited by 53
Namanja, A. T., Wang, J., Buettner, R., Colson, L., & Chen, Y. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.01.003 · Cited by 31
Farooqi, A. A., Rakhmetova, V. S., Kapanova, G., Tashenova, G., Tulebayeva, A., Akhenbekova, A., Ibekenov, O., Turgambayeva, A., & Xu, B. (2023) · Molecules · doi:10.3390/molecules28052231 · Cited by 25
Metadata
- Authors
- Turkson, J., Ryan, D., Kim, J. S., Zhang, Y., Chen, Z., Haura, E., Laudano, A., Sebti, S., Hamilton, A. D., & Jove, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-11
- Volume
- 276
- Issue
- 48
- Pages
- 45443-45455
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2058792197
- Cited by
- 448
- References
- 64
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.